Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

OCRX 6.33 -0.10 (-1.55%)
price chart
Ocera Therapeutics Finally Ready To Reward Investors
The company will be presenting at the Bio Investor Forum on October 7th and should be providing a more precise timeline for top line data.
Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer
PALO ALTO, Calif., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the appointment of Michael Byrnes as ...
Related articles »  
Ocera Therapeutics Well-Capitalized After The Merger
Ocera Therapeutics (NASDAQ:OCRX) announced the closing of a merger with Tranzyme on July 15. Immediately following the closing of the merger, certain of the Ocera investors invested approximately $20 million in the company through a private ...
Can the Rally in Ocera Therapeutics (OCRX) Shares Continue?
Ocera Therapeutics Inc (OCRX - Snapshot Report) has been on the move lately as the stock has risen by 8.9% in the past four weeks, and it is currently trading well above its 20-Day SMA.
Ocera Therapeutics: A Potential Multibagger Biopharmaceutical Company
Ocera Therapeutics [Nasdaq: (NASDAQ:OCRX)] announced the initiation of its phase 2b double blind, controlled, randomized clinical trial in early January 2014.
Related articles »  
Ocera Therapeutics (OCRX) Worth Watching: Stock Up 9.4%
Ocera Therapeutics, Inc. (OCRX - Snapshot Report) was a big mover last session with its shares rising over 9% on the day.
Related articles »  
Ocera Therapeutics Announces Appointment of Steven P. James to Board
PALO ALTO, Calif., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Steven P. James has been ...
Related articles »  
Stocks Underperform for the Week: Ocera Therapeutics Inc , Deltic Timber Corp
Ocera Therapeutics Inc (NASDAQ:OCRX) has dropped 0.8% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 6.33% in the past 4 weeks.
Ocera Therapeutics Announces Completion of Merger With Tranzyme
SAN DIEGO, July 15, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. ("Ocera"), a clinical stage biopharmaceutical company developing novel therapeutics for orphan liver diseases, and Tranzyme, Inc. (Nasdaq:TZYM) ("Tranzyme") today announced ...
Related articles »  
Ocera Therapeutics Announces Appointment of Gaurav Aggarwal, MD, as Chief ...
PALO ALTO, Calif., May 2, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that Gaurav Aggarwal, M.D.
Related articles »